These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38551188)

  • 1. Global experience of faricimab in clinical settings - a review.
    Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
    Expert Opin Biol Ther; 2024 Apr; 24(4):263-268. PubMed ID: 38551188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
    Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR
    Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study.
    Grimaldi G; Cancian G; Rizzato A; Casanova A; Perruchoud-Ader K; Clerici M; Consigli A; Menghini M
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1151-1159. PubMed ID: 38047930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
    Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA;
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
    Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
    Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
    Khanani AM; Aziz AA; Khan H; Gupta A; Mojumder O; Saulebayeva A; Abbey AM; Almeida DRP; Avery RL; Banda HK; Barakat MR; Bhandari R; Chang EY; Haug SJ; London NJS; Mein L; Sheth VS; Wolfe JD; Singer MA; Danzig CJ
    Eye (Lond); 2023 Dec; 37(17):3574-3581. PubMed ID: 37173428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
    Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
    Heier JS; Khanani AM; Quezada Ruiz C; Basu K; Ferrone PJ; Brittain C; Figueroa MS; Lin H; Holz FG; Patel V; Lai TYY; Silverman D; Regillo C; Swaminathan B; Viola F; Cheung CMG; Wong TY;
    Lancet; 2022 Feb; 399(10326):729-740. PubMed ID: 35085502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
    Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
    Liberski S; Wichrowska M; Kocięcki J
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faricimab: First Approval.
    Shirley M
    Drugs; 2022 May; 82(7):825-830. PubMed ID: 35474059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration.
    Tamiya R; Hata M; Tanaka A; Tsuchikawa M; Ueda-Arakawa N; Tamura H; Miyata M; Takahashi A; Kido A; Muraoka Y; Miyake M; Ooto S; Tsujikawa A
    Sci Rep; 2023 Nov; 13(1):21128. PubMed ID: 38036627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME.
    Penha FM; Masud M; Khanani ZA; Thomas M; Fong RD; Smith K; Chand A; Khan M; Gahn G; Melo GB; Khanani AM
    Int J Retina Vitreous; 2024 Jan; 10(1):5. PubMed ID: 38233896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.
    Khan M; Aziz AA; Shafi NA; Abbas T; Khanani AM
    Cells; 2020 Aug; 9(8):. PubMed ID: 32785136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Nagashima T; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2945-2952. PubMed ID: 37195339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials.
    Li G; Zhu N; Ji A
    Medicine (Baltimore); 2023 Dec; 102(50):e36370. PubMed ID: 38115358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review.
    Nasimi N; Nasimi S; Grauslund J; Vergmann AS; Subhi Y
    Int J Retina Vitreous; 2024 Jul; 10(1):48. PubMed ID: 38997766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
    JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Wykoff CC; Abreu F; Adamis AP; Basu K; Eichenbaum DA; Haskova Z; Lin H; Loewenstein A; Mohan S; Pearce IA; Sakamoto T; Schlottmann PG; Silverman D; Sun JK; Wells JA; Willis JR; Tadayoni R;
    Lancet; 2022 Feb; 399(10326):741-755. PubMed ID: 35085503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.